- Glaukos reported past third quarter 2026 sales of US$211.03 million, a quarterly net income of US$2.02 million, and raised full year 2026 net sales guidance to a range of US$775 million to US$785 million, while also setting a preliminary 2027 revenue target of US$1 billion.
- The business is now seeing iDose TR and Epioxa generate enough contribution to cover heavier spending, with glaucoma and corneal health franchises supporting improved earnings per share and giving management room to plan around reimbursement, access, and pipeline build out.
- We will now see how the Glaukos investment narrative could be reshaped by the stronger quarterly profitability and the higher multi year sales targets.
Scan how Glaukos fits into a broader medtech momentum story by comparing it with a hand picked 34 healthcare AI stocks that are also leaning on new treatments and platforms to reshape earnings profiles.
Glaukos Investment Narrative Recap
To own Glaukos you need to believe the interventional ophthalmology thesis holds together. That means iDose TR and Epioxa continue to support a business that can fund heavy R&D and commercial investment from its own cash generation. The latest quarter put real numbers behind that idea, with record sales and a move to positive earnings per share.
The near term swing factor remains reimbursement and payer execution for both iDose TR and Epioxa. Third quarter profitability helps Glaukos absorb potential friction if Medicare coverage decisions or prior authorization hurdles slow procedures. It does not remove that risk. It simply buys more time and flexibility to respond.
The raised 2026 net sales outlook to US$775 million to US$785 million looks like the announcement that matters most for this update. It explicitly ties the strong third quarter performance to a higher run rate for the glaucoma and corneal health franchises, while still acknowledging reimbursement work ahead.
For you as an investor, that guidance resets the operational bar. In the near term, the key question is whether payer coverage, Local Coverage Determinations for iDose TR, and Epioxa workflow issues allow Glaukos to land within that range. Progress in these areas influences how credible the preliminary 2027 US$1b sales target appears as an operational waypoint.
Glaukos' narrative projects US$1.2b revenue and US$138.6 million earnings by 2029. This assumes revenue grows at 25.7% per year and earnings increase by about US$326.6 million from a loss of US$188.0 million today.
Uncover why Glaukos' fair value indicates a 16% potential downside to its current price, which leaves little room for error.
Exploring Other Perspectives
Glaukos looks very different through the most bearish lens. Those analysts worry less about the latest profit print and more about a longer reimbursement drag, which is why they were only penciling in about US$1.2b revenue and US$120.1 million earnings by 2029. That is a meaningfully harsher story than consensus. Use this third quarter surprise as a prompt to compare those pre news estimates with your own expectations and to explore which narrative feels closer to how you see the business.
Explore 3 other Glaukos fair value estimates, including one that suggests as much as 26% downside from the current price.
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own research and judgment.
- A great starting point for your Glaukos research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Glaukos. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Glaukos' overall financial health at a glance.
Looking for more Glaukos-like investment ideas?
If the Glaukos story has sharpened your thinking about risk, reward, and execution, it can help to line it up against a broader watchlist. Use the Simply Wall St Screener to compare this stock with peers that fit different objectives, from long term compounding to steadier income or lower volatility.
- For investors who care most about quality and price discipline, scan a curated group of 29 high quality undervalued stocks that combine stronger fundamentals with more conservative valuations.
- If capital preservation and balance sheet strength sit at the top of your checklist, build a shortlist using a list of solid balance sheet and fundamentals (25 results) that can support growth plans through a wide range of conditions.
- Those hunting for opportunities earlier in their lifecycle can focus on selectively higher risk ideas by filtering for 9 elite penny stocks with strong financials that already show improving financial profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com